TB-500 vs BPC-157: How the Two Research Peptides Differ

For laboratory research use only. Not for human consumption.

TB-500 and BPC-157 are often mentioned in the same breath, and they're sometimes supplied together in a single blend vial. That pairing makes it easy to assume they're related molecules. They aren't. They come from different parent proteins, have different lengths and molecular weights, and they've been studied in separate bodies of literature. This guide sets out the differences that matter to a laboratory: what each molecule is, where it came from, and how an analytical certificate tells them apart.

It does not cover human use, administration or any health outcome. None of that is within the scope of a research reference.

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide, meaning it is made of fifteen amino acids. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and its molecular weight is around 1419.5 Da. A 2025 literature and patent review traces the sequence to a protein fraction first described in human gastric juice. The same review notes the sequence has no homology with known intestinal peptides (literature and patent review, 2025, PMC11859134).

The review also says the peptide has been reported as relatively stable in aqueous solution. That's an unusual property for a short peptide, and it's one reason BPC-157 shows up in studies of peptide stability and formulation.

Where BPC-157 sits in the literature

Almost all published BPC-157 work is preclinical, mostly in rodent models, and a large share comes from a small number of research groups. A 2025 narrative review counted only three published human reports. All three were small and uncontrolled, and the authors flagged major methodological limitations (narrative review, PMC12446177). Researchers should treat the literature as early-stage and read individual papers critically.

What is TB-500?

"TB-500" is a trade name rather than a systematic chemical name, and products sold under it haven't always been clearly characterised. The most cited analytical work on the question is Esposito et al. (2012) in Drug Testing and Analysis. Using high-resolution mass spectrometry, the authors found that the TB-500 product they tested did not contain full-length thymosin beta-4 (Tβ4, a 43-residue protein of about 4963 Da). It contained the N-terminally acetylated heptapeptide Ac-LKKTETQ, which corresponds to residues 17–23 of Tβ4, with a molecular weight of about 888.5 Da (Esposito et al., 2012, doi:10.1002/dta.1402).

The parent protein: thymosin beta-4

Thymosin beta-4 is best known in cell biology as a major actin-sequestering protein. It binds monomeric G-actin and regulates the pool available for filament assembly. Goldstein, Hannappel and Kleinman reviewed its properties in Trends in Molecular Medicine (2005, PMID 16099219). Residues 17–23 include the region associated with actin binding.

A seven-residue fragment isn't the 43-residue protein, though. Findings published for full-length Tβ4 shouldn't be assumed to apply to the fragment, and the reverse is also true. When you review literature, check which molecule each study actually used.

Side-by-side comparison

Property	BPC-157	TB-500 (as characterised by Esposito et al.)
Length	15 amino acids	7 amino acids
Sequence	GEPPPGKPADDAGLV*	Ac-LKKTETQ
Approx. molecular weight	~1419.5 Da	~888.5 Da
Parent source	Gastric juice protein fraction	Thymosin beta-4 (residues 17–23)
Terminal modification	None in the standard sequence	N-terminal acetylation
Literature base	Mostly preclinical, a few research groups	Mostly analytical, doping-control and preclinical; parent protein widely studied

*Sequences are often written in different conventions. Always check the sequence printed on the certificate for the specific batch against a primary reference.

Why the difference matters in the lab

Identity confirmation

The two compounds differ in molecular weight by roughly 530 Da, so mass spectrometry tells them apart easily. A high HPLC purity figure on its own does not confirm which peptide is in the vial. It only describes the proportion of the main peak. For identity, look for a mass result that matches the expected molecular weight. Our guide to HPLC purity vs compound identity covers this in more detail.

Blends and quantitation

When both peptides are supplied in one vial, each component needs to be identified and ideally quantified separately. A single purity figure for a two-component blend can be hard to interpret. Our article on single compounds vs research peptide blends explains what to look for on a blend certificate.

Doping-control context

TB-500 appears in the analytical literature largely because of anti-doping laboratories. Esposito et al. developed their characterisation for detection purposes, and equine doping-control methods have also been published. Australian researchers working in sport-science settings should know that both compounds appear on prohibited lists maintained by anti-doping authorities.

Australian regulatory context

Researchers in Australia should know the current position. The TGA has stated that "research use only" or "not for human use" labels don't change whether a product is regulated as a therapeutic good (TGA – How we regulate therapeutic peptide products). Neither compound is included on the Australian Register of Therapeutic Goods. Check your institutional and legal obligations before purchasing.

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Analytical work by Esposito et al. (2012) found that a product sold as TB-500 contained an acetylated seven-residue fragment (residues 17–23) of thymosin beta-4, not the full 43-residue protein.

What is the molecular weight difference between BPC-157 and TB-500?

BPC-157 is about 1419.5 Da and the characterised TB-500 fragment is about 888.5 Da. Mass spectrometry can easily resolve a difference of that size.

Can HPLC alone tell BPC-157 and TB-500 apart?

HPLC purity shows how much of the sample is the main peak. It doesn't confirm what that peak is. Identity is normally confirmed by mass spectrometry against the expected mass.

Why are BPC-157 and TB-500 supplied as a blend?

Some suppliers offer them combined for convenience. For research purposes, a blend certificate should ideally report the identity and amount of each component separately.

Is the published research on these peptides in humans?

Very little of it. The BPC-157 literature is mostly preclinical, and recent reviews identify only a handful of small, uncontrolled human reports. For TB-500 the literature is mainly analytical and preclinical.

Confirm your age